Rinvoq found most effective for active AS, regardless of TNFi use
Rinvoq (upadacitinib) appears to be the most effective treatment to reduce disease activity in people with ankylosing spondylitis (AS), whether they had never been on tumor necrosis factor inhibitors (TNFi) or didn’t respond well to them, a study suggests. Because the observations come from indirect comparisons of data…